Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Notes Payables (2021)

Coherus Oncology's Notes Payables history spans 2 years, with the latest figure at $81.0 million for Q3 2021.

  • For Q3 2021, Notes Payables changed N/A year-over-year to $81.0 million; the TTM value through Sep 2021 reached $81.0 million, changed N/A, while the annual FY2013 figure was $1.1 million, N/A changed from the prior year.
  • Notes Payables for Q3 2021 was $81.0 million at Coherus Oncology, roughly flat from $80.6 million in the prior quarter.
  • Across five years, Notes Payables topped out at $81.0 million in Q3 2021 and bottomed at $80.2 million in Q1 2021.